Chen YH, Farnham PG, Hicks KA, Sansom SL. Estimating the HIV effective reproduction number in the United States and evaluating HIV elimination strategies. J Public Health Manag Pract. 2022 Mar;28(2). doi: 10.1097/PHH.0000000000001397
Lewis JH, Whelihan K, Roy D, White EJ, Morgan C, Vora RS, Boyle KR, Luebbering C, Bay RC, Lindley MC. Vaccination capability inventory of community, migrant, and homeless health centers: a survey report. J Public Health Manag Pract. 2020 Mar;26(2):139-47. doi: 10.1097/PHH.0000000000001073
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Jacobson EU, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Effects of reaching national goals on HIV incidence, by race and ethnicity, in the United States. J Public Health Manag Pract. 2018 Jul;24(4):E1-8. doi: 10.1097/PHH.0000000000000717
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Hong J, Novick D, Montgomery W, Aguado J, Dueñas H, Peng X, Haro JM. Should unexplained painful physical symptoms be considered within the spectrum of depressive symptoms? Clin Pract Epidemiol Ment Health. 2015 Mar 31;11:130-9. doi: 10.2174/1745017901511010130
Cilenti D, Kum HC, Wells R, Whitmire JT, Goyal RK, Hillemeier MM. Changes in North Carolina maternal health service use and outcomes among medicaid-enrolled pregnant women during state budget cuts. J Public Health Manag Pract. 2015 Mar;21(2):208-13. doi: 10.1097/PHH.0000000000000118
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Cho BH, Hicks KA, Honeycutt AA, Hupert N, Khavjou O, Messonnier M, Washington ML. A Tool for the Economic Analysis of Mass Prophylaxis Operations With an Application to H1N1 Influenza Vaccination Clinics. J Public Health Manag Pract. 2011 Jan 1;17(1):E22-8.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.